Radioactive cancer drug enters first human trials
NCT ID NCT07232407
Summary
This is a first-in-human study to test the safety and early effectiveness of a new radioactive drug called Lutetium BL-ARC001. It is for adults with advanced gastrointestinal cancers or other solid tumors that have spread or cannot be surgically removed. The main goals are to find a safe dose and see how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sichuan Cancer Hospital
RECRUITINGChengdu, Sichuan, China
Contact
Conditions
Explore the condition pages connected to this study.